Cargando…

Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report

Antiandrogen withdrawal syndrome (AWS) is a well-established phenomenon in prostate cancer treated with combined androgen blockade (CAB). AWS is generally defined as subjective and/or objective improvement following discontinuation of an antiandrogen. However, the duration of the AWS response is usu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sano, Masayuki, Yamamoto, Shinya, Uehara, Sho, Yuasa, Takeshi, Masuda, Hitoshi, Fukui, Iwao, Yonese, Junji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997963/ https://www.ncbi.nlm.nih.gov/pubmed/27588183 http://dx.doi.org/10.3892/mco.2016.946

Ejemplares similares

Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer
por: Uehara, Sho, et al.
Publicado: (2015)

Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
por: Yamasaki, Mutsushi, et al.
Publicado: (2016)

A case of gastric metastasis from renal cell cancer during the sequential targeted therapy
por: Uehara, Sho, et al.
Publicado: (2017)

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high
por: Fujiwara, Motohiro, et al.
Publicado: (2020)

Denosumab: a new option in the treatment of bone metastases from urological cancers
por: Yuasa, Takeshi, et al.
Publicado: (2012)

Clinical outcome of patients with pancreatic metastases from renal cell cancer
por: Yuasa, Takeshi, et al.
Publicado: (2015)

Biomarkers to predict prognosis and response to checkpoint inhibitors
por: Yuasa, Takeshi, et al.
Publicado: (2017)

Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer
por: Yamamoto, Shinya, et al.
Publicado: (2013)

Recent advances in medical therapy for metastatic urothelial cancer
por: Yuasa, Takeshi, et al.
Publicado: (2018)

Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single‐center analysis in Japan
por: Fujiwara, Motohiro, et al.
Publicado: (2021)

External validation of the Briganti 2019 nomogram to identify candidates for extended pelvic lymph node dissection among patients with high-risk clinically localized prostate cancer
por: Fukagawa, Eri, et al.
Publicado: (2021)

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
por: Boudadi, Karim, et al.
Publicado: (2016)

A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome
por: Oki, Ryosuke, et al.
Publicado: (2022)

Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+ regulatory T cells in renal cell carcinoma
por: Inamura, Kentaro, et al.
Publicado: (2019)

Testicular seminoma with a progressing pulmonary nodule and mediastinal lymphadenopathy without retroperitoneal metastasis
por: Sano, Yuta, et al.
Publicado: (2020)

A dramatic, objective antiandrogen withdrawal response: case report and review of the literature
por: Lau, Yiu-Keung, et al.
Publicado: (2008)

The utility of diffusion‐weighted whole‐body imaging with background body signal suppression in detecting metastatic lesion of germ cell carcinoma
por: Yoshitomi, Kasumi Kaneko, et al.
Publicado: (2021)

Impact of Serum γ-Glutamyltransferase on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel
por: Une, Minami, et al.
Publicado: (2021)

Diagnostic performance of a computer-assisted diagnosis system for bone scintigraphy of newly developed skeletal metastasis in prostate cancer patients: search for low-sensitivity subgroups
por: Koizumi, Mitsuru, et al.
Publicado: (2017)

De novo large‐cell neuroendocrine carcinoma of the prostate: A case report and literature review
por: Fukagawa, Eri, et al.
Publicado: (2022)

Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?
por: Maitland, Norman J.
Publicado: (2021)

Rational Second-Generation Antiandrogen Use in Prostate Cancer
por: Orme, Jacob J, et al.
Publicado: (2022)

Therapeutic inhibition of mitochondrial function induces cell death in starvation-resistant renal cell carcinomas
por: Isono, Takahiro, et al.
Publicado: (2016)

Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
por: Chen, Xiangyu, et al.
Publicado: (2023)

Early onset recall pneumonitis during targeted therapy with sunitinib
por: Yuasa, Takeshi, et al.
Publicado: (2013)

Comparison Between Dose-Escalated Intensity Modulated Radiation Therapy and 3-Dimensional Conformal Radiation Therapy for Salvage Radiation Therapy After Prostatectomy
por: Shimoyachi, Nana, et al.
Publicado: (2021)

Unusual metastasis from renal cell cancer after partial nephrectomy and sequential targeted therapy
por: Yasuoka, Shotaro, et al.
Publicado: (2021)

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms
por: Verma, Shiv, et al.
Publicado: (2020)

Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
por: Kim, Isaac E., et al.
Publicado: (2021)

Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen
por: Takeda, Keisuke, et al.
Publicado: (2016)

Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants – In vivo evidence
por: Özten-Kandaş, Nur, et al.
Publicado: (2011)

Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
por: Semenas, Julius, et al.
Publicado: (2013)

Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade
por: Flaig, Thomas W., et al.
Publicado: (2017)

Association of Second-generation Antiandrogens With Depression Among Patients With Prostate Cancer
por: Nowakowska, Malgorzata K., et al.
Publicado: (2021)

Role of prostate cancer stem-like cells in the development of antiandrogen resistance
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy
por: Congregado Ruiz, Belén, et al.
Publicado: (2023)

Complete Response to Bicalutamide Withdrawal Prolonged for Almost 2 Years in Patients With Metastatic Prostate Cancer()
por: Hongo, Hiroshi, et al.
Publicado: (2014)

Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study
por: Fukushima, Hiroshi, et al.
Publicado: (2020)

Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer
por: Zhang, Zeda, et al.
Publicado: (2020)

Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?
por: Yekedüz, Emre, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hq3mihela49qd2h0uoo3blss55